# Furthering CSRC Initiatives A Role for the ACC





### What We Do...

- Quality Care: Leading the way in defining quality care for the cardiovascular community and patients
- Education: Providing the very best cardiovascular knowledge for every clinician
- Advocacy: Shaping the future of health care nationwide to increase patient value and access to quality care







# SAFARI incubator to birth

SAFE-PCI incubator to birth and beyond



### SAFARI – Part One

Safety of
Atrial
Fibrillation
Ablation
Registry
Initiative

- Originally convened via CSRC (DCRI, ACC, HRS, STS, NHLBI, FDA, CMS, and AHRQ)
- Safety and effectiveness of AF ablation procedures
- Houston we have a problem..




### SAFARI – Part Two

### **Executive Committee**

FDA support Inclusion criteria, metrics and dataset Pilot test of data collection (10 sites)

Implementation plan for registry development Follow-up data collection feasibility study



### NCRI Mission

Integrate existing resources to efficiently execute large, simple clinical research projects

- Site recruitment and education
- Randomization, Research Data Collection
- Quality Improvement Registry Data collection
- Data standards submissions
- Research opportunity development
- Reusable



### NCRI's infrastructure opens doors...

# Site Descriptor Database

- · Database of research ready sites within the NCDR
- An approach for targeted recruitment

### Data Transfer System

- Connects CathPCI with an EDC System
- · Provides mechanism for modified CRFs, additional data collection

### Randomization

Connection with EDC system allows us to track randomized patients within the registry

### SDTM Output

 Data Collection tool/ EDC system that can export data in SDTM compliant structure (ready for FDA submission)

### Data Standards

- Create CV standards in CDISC and HL7
- Load all standards in NCI repository for future uses in trials

## Enhance Site Research Readiness

 Employ educational webinars/ training to NCDR sites to become research ready


### Future Research

- Ready for large randomized clinical trials
- Post approval studies and CER



# Trans-Radial Education And Therapeutics (TREAT) Initiative Thinktank/Incubator II

### The SAFE-PCI for Women



# SAFE-PCI for Women Study

Study of Access Site

**F**or

**E**nhancement of

**P**ercutaneous

Coronary


Intervention for Women

### **DCRI**

Study Coordinating Center

### ACC

 Registry Platform





### NCRI infrastructure at work for SAFE-PCI...

- Execute Data Release Consent Form (DRCF)
   with sites allowing transfer of CathPCI data
- Populate SDD with research ready sites
- Timely data transfer of CathPCI data to DCRI
- Clinical support -triage data entry questions
- Program support-triage study questions

### **SAFE-PCI Milestones**

### SDD

Site Descriptor
 Database (SDD)
 housing ≈ 50
 research ready
 CathPCI
 Registry® sites

#### Enrollment

 First active and enrolling site September 2011

### Patient randomization

 First patient randomized September 2011


### CathPCI

 Successful merge of CathPCI Registry® data with study specific data from DCRI EDC system

### Timing

 ≈24 month subject enrollment; 3-6 month site enrollment

# Clinical registries provide a platform for phase 3 & 4 research studies...



- Safety is primary endpoint
- Small sample Size (n < 20)</li>
- Highly selected population (must meet several selection criteria)
- Short duration

- Safety and efficacy are primary endpoints
- Limited sample size (n ~ 25-50)
- Highly selected population
- Short duration

- Safety and efficacy are primary endpoints
- Larger sample size to test hypotheses (n ~ 150-250)
- Selected population
- Pivotal studies (randomized controlled trial, RCT)
- Longer duration

- FDA driven and negotiated
- Centers defined
- Generally a Phase 3 continuance
- Sample size pre-determined
- Study interval defined

- · Sponsor driven
- Generally RCT or Claims based
- Direct product comparisons
- Costs collected
- Sample size pre-determined
- Study interval defined

- Product performance and safety data
- or Claims based Effectiveness is the Direct product primary endpoint
  - Hypothesis generating
  - Large and usually undefined sample size
  - Real world population
  - · Continuous duration
  - Treatment not assigned

# Thank you



